A Dual Cytotoxic Chemotherapy & Immunomodulator for Hepatocellular Carcinoma
BackgroundHepatocellular carcinoma (HCC) is the most common primary liver cancer. In the U.S., approximately 40,000 people are diagnosed annually, and 70,000 people are living with HCC.
Half of the people diagnosed with hepatocellular carcinoma will die within two years. Only 18% of people live past five years.
Current treatments are limited by hepatotoxicity and acquired resistance, leading to treatment failure in 95% people.
Our ApproachBG-200A is a novel small molecule with the potential to overcome the hepatotoxicity and resistance limitations of current
hepatocellular carcinoma treatments.
BG-200A selectively kills HCC cells and inhibits their proliferation, while sparing healthy liver cells. BG-200A also directly recruits cytotoxic immune cells, activating the immune system, to clear HCC naturally.
Potential ImpactBG-200A’s dual mechanism of action could extend survival and improve outcomes for HCC patients, to capture a significant share of the $3.8 billion global HCC therapeutics market.
StatusPreclinical.
biOOrg3.14 is actively seeking investment and strategic partnerships to accelerate clinical development of BG-200A.